Financial Performance - Black Diamond ended 2024 with approximately $98.6 million in cash, cash equivalents, and investments, down from $131.4 million as of December 31, 2023[4]. - Net cash used in operations for the year ended December 31, 2024, was $62.3 million, compared to $66.7 million for the year ended December 31, 2023[4]. - Total operating expenses for the year ended December 31, 2024, were $78.8 million, down from $86.5 million in 2023, reflecting a reduction of 8.0%[15]. - Net loss for Q4 2024 was $16.0 million, compared to a net loss of $19.4 million for the same period in 2023, representing a 17.5% improvement[10]. - The accumulated deficit increased to $487.1 million as of December 31, 2024, from $417.4 million in 2023[13]. Research and Development - Research and development expenses for Q4 2024 were $12.3 million, a decrease of 19.5% from $15.3 million in Q4 2023[10]. - Black Diamond anticipates initial Phase 2 clinical data for BDTX-1535 in newly diagnosed patients with non-classical EGFRm NSCLC in Q2 2025[5]. - The company plans to solicit FDA feedback on a potential pivotal registrational path for BDTX-1535 in the second half of 2025[6]. - The expansion of the investigator-sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients is expected in Q1 2025[5]. Cash Position - Black Diamond's cash position is expected to be sufficient to fund operations into Q4 2026[7].
Black Diamond Therapeutics(BDTX) - 2024 Q4 - Annual Results